Welcome!

News Feed Item

Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02256135/Lower-Limb-Muscle-Spasticity-Global-Clinical-Trials-Review-H2-2014.html

Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014" provides data on the Lower Limb Muscle Spasticity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lower Limb Muscle Spasticity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lower Limb Muscle Spasticity. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Lower Limb Muscle Spasticity 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10

Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials by E7 Countries: Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials 16
Clinical Trials by Phase in E7 Countries 17
Clinical Trials in E7 Countries by Trial Status 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20

Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Lower Limb Muscle Spasticity Therapeutics Clinical Trials 26
Prominent Drugs 27
Clinical Trial Profiles 28
Clinical Trial Overview of Top Companies 28
Merz Pharma GmbH & Co. KgaA 28
Clinical Trial Overview of Merz Pharma GmbH & Co. KgaA 28
Ipsen S.A. 29
Clinical Trial Overview of Ipsen S.A. 29
Allergan, Inc. 30
Clinical Trial Overview of Allergan, Inc. 30
GlaxoSmithKline plc 31
Clinical Trial Overview of GlaxoSmithKline plc 31
Clinical Trial Overview of Top Institutes / Government 32
The University of Tokushima 32
Clinical Trial Overview of The University of Tokushima 32

Tehran University of Medical Sciences 33
Clinical Trial Overview of Tehran University of Medical Sciences 33
Danish Pain Research Center 34
Clinical Trial Overview of Danish Pain Research Center 34
Assistance Publique Hopitaux De Marseille 35
Clinical Trial Overview of Assistance Publique Hopitaux De Marseille 35
Five Key Clinical Profiles 36
Appendix 112
Abbreviations 112
Definitions 112
Research Methodology 113
Secondary Research 113
About GlobalData 114
Contact Us 114
Disclaimer 114
Source 114

List of Tables

Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Region, 2014* 6
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 9
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 12

Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 13
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Lower Limb Muscle Spasticity Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 17
Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 18
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Phase, 2014* 19
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 20
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23

Lower Limb Muscle Spasticity Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 24
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Merz Pharma GmbH & Co. KgaA, 2014* 28
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Ipsen S.A., 2014* 29
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2014* 30
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 31
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Tokushima, 2014* 32
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 33
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Danish Pain Research Center, 2014* 34
Lower Limb Muscle Spasticity Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique Hopitaux De Marseille, 2014* 35

List of Figures

Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 9
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 11
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 12
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Lower Limb Muscle Spasticity Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Proportion of Lower Limb Muscle Spasticity to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 17

Lower Limb Muscle Spasticity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 18
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Phase (%), 2014* 19
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 20
Lower Limb Muscle Spasticity Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Lower Limb Muscle Spasticity Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 24
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Lower Limb Muscle Spasticity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
GlobalData Methodology 113

To order this report: Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02256135/Lower-Limb-Muscle-Spasticity-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Apache Hadoop is a key technology for gaining business insights from your Big Data, but the penetration into enterprises is shockingly low. In fact, Apache Hadoop and Big Data proponents recognize that this technology has not yet achieved its game-changing business potential. In his session at 19th Cloud Expo, John Mertic, director of program management for ODPi at The Linux Foundation, will explain why this is, how we can work together as an open data community to increase adoption, and the i...
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walk you through how Oct...
There is growing need for data-driven applications and the need for digital platforms to build these apps. In his session at 19th Cloud Expo, Muddu Sudhakar, VP and GM of Security & IoT at Splunk, will cover different PaaS solutions and Big Data platforms that are available to build applications. In addition, AI and machine learning are creating new requirements that developers need in the building of next-gen apps. The next-generation digital platforms have some of the past platform needs a...
Smart Cities are here to stay, but for their promise to be delivered, the data they produce must not be put in new siloes. In his session at @ThingsExpo, Mathias Herberts, Co-founder and CTO of Cityzen Data, will deep dive into best practices that will ensure a successful smart city journey.
Businesses are struggling to manage the information flow and interactions between all of these new devices and things jumping on their network, and the apps and IT systems they control. The data businesses gather is only helpful if they can do something with it. In his session at @ThingsExpo, Chris Witeck, Principal Technology Strategist at Citrix, will discuss how different the impact of IoT will be for large businesses, expanding how IoT will allow large organizations to make their legacy ap...
Adobe is changing the world though digital experiences. Adobe helps customers develop and deliver high-impact experiences that differentiate brands, build loyalty, and drive revenue across every screen, including smartphones, computers, tablets and TVs. Adobe content solutions are used daily by millions of companies worldwide-from publishers and broadcasters, to enterprises, marketing agencies and household-name brands. Building on its established design leadership, Adobe enables customers not o...
SYS-CON Events announced today that Tintri Inc., a leading producer of VM-aware storage (VAS) for virtualization and cloud environments, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Tintri VM-aware storage is the simplest for virtualized applications and cloud. Organizations including GE, Toyota, United Healthcare, NASA and 6 of the Fortune 15 have said “No to LUNs.” With Tintri they mana...
Major trends and emerging technologies – from virtual reality and IoT, to Big Data and algorithms – are helping organizations innovate in the digital era. However, to create real business value, IT must think beyond the ‘what’ of digital transformation to the ‘how’ to harness emerging trends, innovation and disruption. Architecture is the key that underpins and ties all these efforts together. In the digital age, it’s important to invest in architecture, extend the enterprise footprint to the cl...
Just over a week ago I received a long and loud sustained applause for a presentation I delivered at this year’s Cloud Expo in Santa Clara. I was extremely pleased with the turnout and had some very good conversations with many of the attendees. Over the next few days I had many more meaningful conversations and was not only happy with the results but also learned a few new things. Here is everything I learned in those three days distilled into three short points.
SYS-CON Events announced today that Numerex Corp, a leading provider of managed enterprise solutions enabling the Internet of Things (IoT), will exhibit at the 19th International Cloud Expo | @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Numerex Corp. (NASDAQ:NMRX) is a leading provider of managed enterprise solutions enabling the Internet of Things (IoT). The Company's solutions produce new revenue streams or create operating...
24Notion is full-service global creative digital marketing, technology and lifestyle agency that combines strategic ideas with customized tactical execution. With a broad understand of the art of traditional marketing, new media, communications and social influence, 24Notion uniquely understands how to connect your brand strategy with the right consumer. 24Notion ranked #12 on Corporate Social Responsibility - Book of List.
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
As ridesharing competitors and enhanced services increase, notable changes are occurring in the transportation model. Despite the cost-effective means and flexibility of ridesharing, both drivers and users will need to be aware of the connected environment and how it will impact the ridesharing experience. In his session at @ThingsExpo, Timothy Evavold, Executive Director Automotive at Covisint, will discuss key challenges and solutions to powering a ride sharing and/or multimodal model in the a...
In his general session at 18th Cloud Expo, Lee Atchison, Principal Cloud Architect and Advocate at New Relic, discussed cloud as a ‘better data center’ and how it adds new capacity (faster) and improves application availability (redundancy). The cloud is a ‘Dynamic Tool for Dynamic Apps’ and resource allocation is an integral part of your application architecture, so use only the resources you need and allocate /de-allocate resources on the fly.
DevOps and microservices are permeating software engineering teams broadly, whether these teams are in pure software shops but happen to run a business, such Uber and Airbnb, or in companies that rely heavily on software to run more traditional business, such as financial firms or high-end manufacturers. Microservices and DevOps have created software development and therefore business speed and agility benefits, but they have also created problems; specifically, they have created software sec...